KRAS mutation allows the stable shift of CRC cells toward glycolysis; thus, it has been proposed that CRC cells carrying KRAS mutations exhibit greater sensitivity to 3-BrPA than CRC cells lacking KRAS mutations [51]. This evidence concerns the gene KRAS and colorectal carcinoma.